As a part of this deal, APL also acquired high profile OTC ... with China National Pharmaceutical Group Corporation (Sinopharm) to divest in its subsidiary company Aurobindo (Datong) Bio Pharma ...

Tata Midcap Growth Fund turns a Rs 1,000 monthly SIP into Rs 1 crore in 30 years. Explore its top holdings, risk profile, and ...

A look at 10-year rolling returns over the past 20 years shows that the Nifty Next 50 Total Return Index (TRI) delivered an ...

Acadia Pharmaceuticals ACAD shares surged 26.5% on Friday after the company announced that the U.S. District Court in ...

The urinary tract infection (UTI) treatment market is estimated to be valued at USD 11.24 billion in 2024. The scope for urinary tract infection (UTI) treatment is predicted to rise at a CAGR of 1.9% ...

Shares of Aurobindo Pharma Ltd fell 2.5 percent to Rs 1,161 in morning trade on May 28 after the company reported an 11 percent increase in revenue and a marginal drop in net profit in the March ...

Aurobindo Pharma's stock experienced a price fall during today's trading session. The stock is currently trading at Rs 1,167.10, reflecting a decrease of 2.02%. This movement places Aurobindo ...

On a fiscal year basis (FY25), Aurobindo Pharma’s PAT increased 10% y-o-y to ₹3,484 crore from ₹3,169 crore in FY24, showing better full year profitability. Annual income at the company ...

GIC Re on Monday posted a 17% decline in net profit to ₹2,183 crore for the fourth quarter ended March 2025. The state-owned ...

Aurobindo Pharma, through its wholly owned subsidiary Apitoria, launched ‘Auro Astra’ a leadership development initiative in collaboration with the Institute of Management Technology ...

The purpose of the incorporation of this wholly owned subsidiary is to expand the biopharma products business in Europe.

Aurobindo Pharma is one such company that derives majority of its sales from The US and hence Aurobindo Pharma was the largest loser in the Pharma Index with share price declining more than 3%.